Literature DB >> 10399200

Combining mortality and longitudinal measures in clinical trials.

D M Finkelstein1, D A Schoenfeld.   

Abstract

Clinical trials often assess therapeutic benefit on the basis of an event such as death or the diagnosis of disease. Usually, there are several additional longitudinal measures of clinical status which are collected to be used in the treatment comparison. This paper proposes a simple non-parametric test which combines a time to event measure and a longitudinal measure so that a substantial treatment difference on either of the measures will reject the null hypothesis. The test is applied on AIDS prophylaxis and paediatric trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399200     DOI: 10.1002/(sici)1097-0258(19990615)18:11<1341::aid-sim129>3.0.co;2-7

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  61 in total

1.  Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations.

Authors:  Roland A Matsouaka; Rebecca A Betensky
Journal:  Stat Med       Date:  2014-11-13       Impact factor: 2.373

2.  Large sample inference for a win ratio analysis of a composite outcome based on prioritized components.

Authors:  Ionut Bebu; John M Lachin
Journal:  Biostatistics       Date:  2015-09-08       Impact factor: 5.899

3.  The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.

Authors:  Gaohong Dong; Lu Mao; Bo Huang; Margaret Gamalo-Siebers; Jiuzhou Wang; GuangLei Yu; David C Hoaglin
Journal:  J Biopharm Stat       Date:  2020-06-17       Impact factor: 1.051

4.  Properties of composite time to first event versus joint marginal analyses of multiple outcomes.

Authors:  Ionut Bebu; John M Lachin
Journal:  Stat Med       Date:  2018-06-28       Impact factor: 2.373

5.  Defining Study Outcomes That Better Reflect Individual Response to Treatment.

Authors:  Konstantia Angelidou; Paul Palumbo; Jane Lindsey; Avy Violary; Moherndran Archary; Linda Barlow; Brian Claggett; Michael Hughes; Lee-Jen Wei
Journal:  Pediatr Infect Dis J       Date:  2018-03       Impact factor: 2.129

Review 6.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

7.  An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.

Authors:  Roland A Matsouaka; Aneesh B Singhal; Rebecca A Betensky
Journal:  Stat Methods Med Res       Date:  2016-12-29       Impact factor: 3.021

8.  A non-human primate model of stroke reproducing endovascular thrombectomy and allowing long-term imaging and neurological read-outs.

Authors:  Justine Debatisse; Océane Wateau; Tae-Hee Cho; Nicolas Costes; Inés Mérida; Christelle Léon; Jean-Baptiste Langlois; Fabrice Taborik; Michaël Verset; Karine Portier; Mohamed Aggour; Thomas Troalen; Marjorie Villien; Nikolaos Makris; Christian Tourvieille; Didier Le Bars; Sophie Lancelot; Joachim Confais; Adrien Oudotte; Norbert Nighoghossian; Michel Ovize; Denis Vivien; Hugues Contamin; Véronique Agin; Emmanuelle Canet-Soulas; Omer Faruk Eker
Journal:  J Cereb Blood Flow Metab       Date:  2020-05-19       Impact factor: 6.200

9.  Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Authors:  David J Lederer; Williamson Z Bradford; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Kenneth F Glasscock; David Kardatzke; Talmadge E King; Lisa H Lancaster; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Jeffrey J Swigris; Paul W Noble
Journal:  Chest       Date:  2015-07       Impact factor: 9.410

10.  A robust method for comparing two treatments in a confirmatory clinical trial via multivariate time-to-event methods that jointly incorporate information from longitudinal and time-to-event data.

Authors:  Benjamin R Saville; Amy H Herring; Gary G Koch
Journal:  Stat Med       Date:  2010-01-15       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.